PRKCG: A Protein Targeted for Alzheimer's Disease (G5582)

Target Name: PRKCG

NCBI ID: G5582

PRKCG

PRKCG: A Protein Targeted for Alzheimer's Disease

PRKCG (PRKCG variant 2) is a protein that is expressed in the brain and plays a role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is known for its ability to interact with the protein tau, which is also involved in the development of Alzheimer's disease.

Research has shown that PRKCG is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. beta-amyloid plaques are composed of abnormal aggregates of the protein tau, as well as other cellular components. The presence of beta-amyloid plaques is thought to contribute to the neurotoxicity and damage caused by the disease.

In addition to its role in the formation of beta-amyloid plaques, PRKCG has also been shown to interact with several other proteins that are involved in the development and progression of Alzheimer's disease. For example, studies have shown that PRKCG can interact with the protein APP, which is also involved in the development of beta-amyloid plaques.

These interactions between PRKCG and other proteins raises the possibility that PRKCG could be a drug target or biomarker for Alzheimer's disease. By targeting PRKCG with drugs, researchers could potentially slow down or even reverse the progression of the disease.

One potential approach to targeting PRKCG is to use small molecules that can modulate its activity. For example, researchers have synthesized a number of small molecules that can interact with PRKCG and alter its function. These molecules have been shown to be effective in reducing the formation of beta-amyloid plaques in animal models of Alzheimer's disease.

While the potential benefits of targeting PRKCG with drugs are significant, there are also potential drawbacks to consider. PRKCG is a protein that is expressed in the brain, and any drugs that target it could potentially have negative effects on other tissues and cells. Additionally, the development of new treatments for Alzheimer's disease is a slow and challenging process, and any treatments that are effective must be carefully tested to ensure their safety and effectiveness.

Overall, PRKCG is an intriguing protein that is being studied for its potential role in the development and progression of Alzheimer's disease. While the use of small molecules to modulate its function is a promising approach, further research is needed to fully understand its role and to develop effective treatments for this debilitating disease.

Protein Name: Protein Kinase C Gamma

Functions: Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance of morphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation and degradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress (By similarity). Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resulting in phase resetting of the cerebral cortex clock (By similarity)

The "PRKCG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKCG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets